MTDX 203
Alternative Names: MTDX-203Latest Information Update: 26 Mar 2024
At a glance
- Originator Montdorex
- Class Amidines; Anti-inflammatories; Antineoplastics
- Mechanism of Action Endoexonuclease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Mar 2024 Montdorex therapeutics working on IND submission in the US and Canada (Montdorex therapeutics pipeline, March 2024)
- 12 Mar 2024 Montdorex therapeutics plans to initiate phase I trial (Montdorex therapeutics pipeline, March 2024)
- 08 Mar 2024 Preclinical trials in Solid tumours in USA (unspecified route) (Montdorex therapeutics pipeline, March 2024)